Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 683-688

  Schulte, Peter F J ^a  

^a Mental Health Services North Holland North   (Netherlands)

Author keywords

Agranulocytosis; Clozapine

Indexed keywords

ANTITHYROID AGENT; CHLORAMPHENICOL; CLOZAPINE; DICLOFENAC; DOBESILATE CALCIUM; FELBAMATE; GRANULOCYTE COLONY STIMULATING FACTOR; MIANSERIN; PHENYLBUTAZONE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; BLOOD DYSCRASIA; DISEASE ASSOCIATION; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MEDICAL DECISION MAKING; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEIZURE; SUICIDE ATTEMPT;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; LEUKOPENIA; MEDLINE; MONITORING, PHYSIOLOGIC; RISK;

EID: 33646243828     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G396     Document Type: Review

References (52)

1. EMEA. Committee for Proprietary Medicinal Products (CMPC) summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Leponex and associated names. EMEA, London, 12-11-2002. www.emea.eu.int/pdfs/human/referral/603402en.pdf (accessed 2005 May 5).
2. Prescribing information. Clozaril (clozapine). November 2004. www.fda.gov/cder/foi/label/2005/019758s0541bl.pdf (accessed 2005 Sept 4).
3. FDA advisors back reduced monitoring for patients on clozapine. Reuters Health Information, June 16, 2003.
4. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-7.
5. Meltzer HY, Anand R, Alphs L. Reducing suicide risk in schizophrenia. Focus on the role of clozapine. CNS Drugs 2000;14:355-65.
6. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
7. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin A. Active monitoring of 12760 clozapine recipients in the UK and Ireland. Br J Psychiatry 1999;175:576-80.
8. Kumar V. Clozaril monitoring systems, registry data and analyses (United States, United Kingdom, & Australia). www.fda.gov/ohrms/dockets/acA)3/ slides/3959S1_02_C-Novartis-Kumar.ppt (accessed 2005 Jul 1).
9. Patel NC, Dorson PG, Bettinger TL. Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 2002;36:1012-5. DOI 10.1345/aph.1A417
10. Kaufman DW, Kelly JP, Shapiro S. Nonnarcotic analgesics and non-steroidal anti-inflammatory drugs. In: Kaufman DW, Kelly JP, Shapiro S, eds. The drug etiology of agranulocytosis and aplastic anemia. Oxford: Oxford University Press, 1991:170-203.
11. Kaufman DW, Kelly JP, Shapiro S. Cardiovascular drugs and diuretics. In: Kaufman DW, Kelly JP, Shapiro S, eds. The drug etiology of agranulocytosis and aplastic anemia. Oxford: Oxford University Press, 1991:226-43.
12. Heimpel H. The diseases. In: Kaufman DW, Kelly JP, Shapiro S, eds. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press, 1991:27-69.
13. Hummer M, Kurz M, Barnas C, Fleischhackker WW. Transient neutropenia induced by clozapine. Psychopharmacol Bull 1992;28:287-90.
14. Simpson GM, Edmond HP, Scarnac JJ. Neuroleptics and antipsychotics. In: Dukes MNG, ed. Meyler's side effects of drugs. 13th ed. Amsterdam: Elsevier Science BV, 1996:117-35.
15. Lamarque V. [Hematologic effects of clozapine: a review of international experience] French. Encephale 1996;22(spec no 6):35-6.
16. Grohmann R, Schmidt LG, Spiess-Kiefer C, Rüther E. Agranulocytosis and signficant leucopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology 1989;99:109-12.
17. Pisciotta AV. Agranulocytosis induced by certain phenothiazine derivates. JAMA 1969;208:1862-8.
18. Coulter DM, Edwards CR. Mianserin and agranulocytosis in New Zealand. Lancet 1990;336:785-7.
19. Ibanez L, Ballarin E, Vidal X, Laporte JR. Agranulocytosis associated with calcium dobesilate: clinical course and risk estimation with the case-control and the case population approaches. Eur J Clin Pharmacol 2000;56:763-7.
20. Laporte JR, Vidal X, Ballarin E, Ibanez L. Possible association between ocular chloramphenicol and aplastic anaemia-the absolute risk is very low. Br J Pharmacol 1998;46:181-4.
21. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 1986;256:1749-57.
22. Risk of agranulocytosis and aplastic anaemia in relation to antithyroid drugs. International Agranulocytosis and Aplastic Anaemia Study. BMJ 1988;297:262-5.
23. Kaufman DW, Kelly JP, Anderson T, Harmson DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265-9.
24. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 1996;60(suppl):23-30.
25. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989;99(suppl):118-21.
26. Gullion G, Yeh HS. Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. J Clin Psychiatry 1994;55:401-5.
27. Gerson SL. G-CSF and the management of clozapine induced agranulocytosis. J Clin Psychiatry 1994;55(suppl B):139-42.
28. Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991;79:366-71.
29. Ban A, Ambrusics A, Pinter G. [Occurrence and clinical course of drug-induced agranulocytosis] German. Folia Haematol Int Mag Klin Morphol Blutforsch 1985;112:90-102.
30. Beauchesne MF, Shalansky SJ. Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 1999;19:299-305.
31. Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. Lancet 1990;336:785-7.
32. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
33. Inman WH. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J 1977;1:1500-5.
34. Statistics Netherlands. Unnatural death by causes. http://statline.cbs. nl/StatWeb/Table.asp?LA=n1&DM=SLNL&PA=37683&D1=0-3,20-21,42-43,68, 90-91,104-105,127-128&D2=0&D3=0&D4=a&STB= G1,G2,G3&HDR=T (accessed 2005 Jul 1).
35. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90.
36. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998;49:1029-33.
37. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol 1995;18(suppl 13):18-24.
38. Meltzer HY, Alphs, L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91. Erratum 2003;60:735.
39. Raymont V. Suicide in schizophrenia: how can research influence training and clinical practice? Psychiatr Bull 2001;25:46-50.
40. Meltzer HY. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 2002;4:279-83.
41. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001;15:127-35.
42. Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998;59(suppl 3):200-8.
43. WHO resource book on mental health, human rights and legislation. World Health Organization, 2005. www.who.int/mental_health/policy/resource_book_MHLeg. pdf (accessed 2005 Sept 9).
44. Appelbaum PS, Grisso T. The MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR). Sarasota, FL: Professional Resource Press, 2001.
45. Kovnick JA, Appelbaum PS, Hoge SK, Leadbetter RA. Competence to consent to research among long-stay inpatients with chronic schizophrenia. Psychiatr Serv 2003;54:1247-52.
46. Dunn LB, Jeste DV. Problem areas in the understanding of informed consent for research: study of middle-aged and older patients with psychotic disorders. Psychopharmacology (Berl) 2003;171:81-5.
47. Roberts LW, Warner TD, Brody JL, Roberts B, Lauriello J, Lyketsos C. Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiatry 2002;159:573-84.
48. Stiles PG, Poythress NG, Hall A, Falkenbach D, Williams R. Improving understanding of research consent disclosures among persons with mental illness. Psychiatr Serv 2001;52:780-5.
49. Wirshing DA, Wirshing WC, Marder SR, Liberman RP, Mintz J. Informed consent: assessment of comprehension. Am J Psychiatry 1998;155:1508-11.
50. Eyler LT, Mirzakhanian H, Jeste DV. A preliminary study of interactive questioning methods to assess and improve understanding of informed consent among patients with schizophrenia. Schizophren Res 2005;75:193-8.
51. Rapley M. Quality of life research. A critical introduction. London: Sage Publications, 2003.
52. Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third-line status for schizophrenia? A decision-analytic model. J Mental Health Policy Econ 2004;7:77-85.